Correction: Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: Results from BSRBR-RA (RMD Open (2017) 3 (e000314) DOI: 10.1136/rmdopen-2016-000314);Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: Results from BSRBR-RA

RMD Open

Volumn 3, Issue 1, 2017, Pages

  Jani, Meghna ^a,b   Dixon, William G ^a,b   Kersley Fleet, Lianne ^a   Bruce, Ian N ^a,b,q   Chinoy, Hector ^a,b   Barton, Anne ^a,b   Lunt, Mark ^a   Watson, Kath ^a   Symmons, Deborah P ^a,b   Hyrich, Kimme L ^a,b   Maiden, Nicola ^c   Price, Tom ^d   Hopkinson, Neil ^e   O'Reilly, Sheila ^f   Hordon, Lesley ^g   Griffiths, Ian ^h   Porter, Duncan ⁱ   Capell, Hilary ^j   Hassell, Andy ^k   Benitha, Romela ^l   Choy, Ernest ^m   Walsh, David ⁿ   Emery, Paul ^o   Knight, Susan ^p   Taggart, Allister ^r   Scott, David ^s   Thompson, Paul ^t   McCrae, Fiona ^u   Goodfellow, Rhian ^v   Kitas, George ^w   Jubb, Ronald ^x   Abernethy, Rikki ^y   Clarke, Shane ^z   Green, Sandra ^z   Sanders, Paul ^aa   Coulson, Amanda ^ab   Harrison, Bev ^ac   Bukhari, Marwan ^ad   Klimiuk, Peter ^ae   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c ANTRIM AREA HOSPITAL   (United Kingdom)

^d ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^e Christchurch Hospital Dorset   (United Kingdom)

^f ROYAL DERBY HOSPITAL   (United Kingdom)

^g Dewsbury and District Hospital   (United Kingdom)

^h FREEMAN HOSPITAL   (United Kingdom)

ⁱ GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^j GLASGOW ROYAL INFIRMARY   (United Kingdom)

^k HAYWOOD HOSPITAL   (United Kingdom)

^l HOPE HOSPITAL   (United Kingdom)

^m KING S COLLEGE HOSPITAL   (United Kingdom)

ⁿ Leeds General Infirmary ^*  (United Kingdom)

^o LEEDS GENERAL INFIRMARY   (United Kingdom)

^p MACCLESFIELD DISTRICT GENERAL HOSPITAL   (United Kingdom)

^q MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^r MUSGRAVE PARK HOSPITAL   (United Kingdom)

^s NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^t POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^u QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^v ROYAL GLAMORGAN HOSPITAL   (United Kingdom)

^w RUSSELLS HALL HOSPITAL   (United Kingdom)

^x SELLY OAK HOSPITAL   (United Kingdom)

^y St Helens Hospital   (United Kingdom)

^z WESTON GENERAL HOSPITAL   (United Kingdom)

^aa WITHINGTON HOSPITAL   (United Kingdom)

^ab Withybush General Hospital   (United Kingdom)

^ac NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^ad ROYAL LANCASTER INFIRMARY   (United Kingdom)

^ae ROYAL OLDHAM HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FOLLOW UP; GLOMERULOPATHY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX DISEASE; INCIDENCE; LEUKOCYTOCLASTIC VASCULITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE EVENT; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; NAILFOLD VASCULITIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RENAL VASCULITIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; UNITED KINGDOM; VASCULITIS;

EID: 85009788843     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2016-000314corr1     Document Type: Erratum

References (30)

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
2. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51.
3. Takase K, Horton SC, Ganesha A, et al. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort. Ann Rheum Dis 2014;73:1695-9.
4. Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010;162:780-5.
5. Hoffmann JHO, Hartmann M, Enk AH, et al. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol 2011;165:1355-8.
6. Ladizinski B, Lee KC. Infliximab-induced urticaria. J Emerg Med 2014;46:691-2.
7. Korswagen LA, Bartelds GM, Krieckaert CLM, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011;63:877-83.
8. De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-51.
9. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73:710-13.
10. Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014;53:213-22.
11. National Institute for Health and Clinical Excellence. Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130). http://guidancenice.org.uk/TA130 (2007).
12. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
13. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008;37:381-7.
14. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009;48:716-20.
15. Dubois' Lupus Erythematosus and Related Syndromes 8th edition - ISBN: 9781437718935| US Elsevier Health Bookshop. http://www.us.elsevierhealth.com/rheumatology/dubois-lupus-erythematosus-and-related-syndromes-expert-consult/9781437718935/ (accessed 4 Apr 2015).
16. Hochberg MC. Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
17. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
18. Mercer LK, Lunt M, Low ALS, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2015;76:1087-93.
19. Goeb V, Berthelot JM, Joly P, et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology 2005;44:823-4.
20. Mor A, Pillinger MH, Wortmann RL, et al. Drug-induced arthritic and connective tissue disorders. Semin Arthritis Rheum 2008;38:249-64.
21. Radić M, Martinović Kaliterna D, Radić J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med 2012;70:12-17.
22. Farragher TM, Lunt M, Plant D, et al. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res 2010;62:664-75.
23. Moulis G, Sommet A, Lapeyre-Mestre M, et al. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology (Oxford) 2014;53:1864-71.
24. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Intern Med 2008;7:301-7.
25. Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:1810-14.
26. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.
27. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977-86.
28. Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-TNF drug level testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol 2015;67:2011-19.
29. Jani M, Isaacs JD, Morgan AW, et al., BRAGGSS. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis 2017;76:208-13.
30. Bartelds G, Krieckaert C. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.